YU21399A - Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže - Google Patents

Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže

Info

Publication number
YU21399A
YU21399A YU21399A YU21399A YU21399A YU 21399 A YU21399 A YU 21399A YU 21399 A YU21399 A YU 21399A YU 21399 A YU21399 A YU 21399A YU 21399 A YU21399 A YU 21399A
Authority
YU
Yugoslavia
Prior art keywords
conjugates
pharmaceutical compositions
prostate cancer
production
application
Prior art date
Application number
YU21399A
Other languages
English (en)
Inventor
Victor M. Garsky
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co.Inc. filed Critical Merck & Co.Inc.
Publication of YU21399A publication Critical patent/YU21399A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Opisani su hemijski konjugati koji sadrže oligopeptide, koji imaju amino kiselinske sekvence koje se selektivno proteolitički cepaju pomoću slobodnog prostata specifičnog antigena (PSA) i poznate citotoksične agense. Takodje su opisane farmaceutske kompozicije koje sadrže navedene konjugate kao i upotreba ovih konjugata u proizvodnji leka korisnog za tretiranje raka prostate i benigne hipertrofije prostate (BPH).
YU21399A 1996-10-30 1997-10-27 Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže YU21399A (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
YU21399A true YU21399A (sh) 2000-03-21

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
YU21399A YU21399A (sh) 1996-10-30 1997-10-27 Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže

Country Status (32)

Country Link
EP (1) EP0942754B1 (sh)
JP (1) JP2000509407A (sh)
KR (1) KR100508199B1 (sh)
AR (1) AR008907A1 (sh)
AT (1) ATE239509T1 (sh)
AU (1) AU726434B2 (sh)
BG (1) BG64768B1 (sh)
BR (1) BR9712589A (sh)
CA (1) CA2268738A1 (sh)
CO (1) CO4930281A1 (sh)
CZ (1) CZ155599A3 (sh)
DE (1) DE69721810T2 (sh)
DK (1) DK0942754T3 (sh)
DZ (1) DZ2333A1 (sh)
EA (1) EA002066B1 (sh)
EE (1) EE03858B1 (sh)
ES (1) ES2196374T3 (sh)
HK (1) HK1024876A1 (sh)
HR (1) HRP970566A2 (sh)
HU (1) HUP0000651A3 (sh)
ID (1) ID21358A (sh)
IL (1) IL129356A0 (sh)
IS (1) IS5025A (sh)
NO (1) NO992069L (sh)
PE (1) PE17399A1 (sh)
PL (1) PL333004A1 (sh)
PT (1) PT942754E (sh)
SK (1) SK57399A3 (sh)
TR (1) TR199901485T2 (sh)
TW (1) TW425286B (sh)
WO (1) WO1998018493A2 (sh)
YU (1) YU21399A (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000333A (et) * 1997-12-02 2001-08-15 Merck & Co., Inc. Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ES2342637T3 (es) * 1998-12-11 2010-07-09 Medarex, Inc. Compuestos profarmacos y procedimiento para su preparacion.
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
JP2003512339A (ja) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体
JP2003512475A (ja) * 1999-10-27 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体の塩形態
PL360826A1 (en) * 2000-03-15 2004-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
US8518891B2 (en) * 2006-11-29 2013-08-27 Longqin Hu Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
JP5734209B2 (ja) * 2009-03-09 2015-06-17 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング プロドラッグ
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
KR102204989B1 (ko) 2012-01-12 2021-01-20 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
CN108289952B (zh) 2015-11-19 2021-02-05 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
EP4267188A1 (en) 2020-12-22 2023-11-01 Cobiores NV Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体

Also Published As

Publication number Publication date
JP2000509407A (ja) 2000-07-25
NO992069L (no) 1999-06-30
BG103436A (en) 2000-04-28
TW425286B (en) 2001-03-11
EP0942754A2 (en) 1999-09-22
ID21358A (id) 1999-05-27
KR20000052970A (ko) 2000-08-25
AU726434B2 (en) 2000-11-09
NO992069D0 (no) 1999-04-29
BG64768B1 (bg) 2006-03-31
HUP0000651A3 (en) 2001-12-28
ES2196374T3 (es) 2003-12-16
IL129356A0 (en) 2000-02-17
EE9900179A (et) 1999-12-15
IS5025A (is) 1999-04-13
HK1024876A1 (en) 2000-10-27
WO1998018493A2 (en) 1998-05-07
CZ155599A3 (cs) 1999-10-13
EA199900428A1 (ru) 2000-02-28
SK57399A3 (en) 2000-01-18
HUP0000651A2 (hu) 2000-06-28
AU5149798A (en) 1998-05-22
BR9712589A (pt) 1999-10-26
AR008907A1 (es) 2000-02-23
EA002066B1 (ru) 2001-12-24
CO4930281A1 (es) 2000-06-27
PT942754E (pt) 2003-08-29
PE17399A1 (es) 1999-02-20
DE69721810T2 (de) 2004-03-11
DK0942754T3 (da) 2003-08-04
KR100508199B1 (ko) 2005-08-17
DE69721810D1 (de) 2003-06-12
PL333004A1 (en) 1999-11-08
EP0942754B1 (en) 2003-05-07
CA2268738A1 (en) 1998-05-07
EE03858B1 (et) 2002-10-15
TR199901485T2 (xx) 1999-08-23
HRP970566A2 (en) 1998-08-31
WO1998018493A3 (en) 1998-07-23
ATE239509T1 (de) 2003-05-15
DZ2333A1 (fr) 2002-12-28

Similar Documents

Publication Publication Date Title
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
NO965592L (no) Nye peptider
AU6045398A (en) Androgen synthesis inhibitors
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BRPI0115953B8 (pt) complexos de derivados de fosfato
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
NO944448L (no) Nye farmasöytiske anvendelser av krill-enzymer
ATE256473T1 (de) Konjugate welche bei der behandlung von prostatakrebs nützlich sind
PT1107996E (pt) Anticorpos humanos anti-factor ix/ixa
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
HUP0100350A2 (hu) A prosztatarák kezelésére alkalmazható konjugátumok, azokat hatóanyagként tartalmazó gyógyászati készítmények, elárás ezek előállítására, valamint alkalmazásuk
DE60305438D1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
HUP0100048A2 (hu) Arilszubsztituált piperazinszármazékok, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
NO20024363L (no) Nye LHRH-antagonister, produksjon og anvendelse av disse som medikamant
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
WO1999044628A8 (en) Conjugates useful in the treatment of prostate cancer